News Briefs: Covis Pharma to Pull Makena

Covis Pharma Group said on March 7 that it will voluntarily stop selling Makena (hydroxyprogesterone caproate), a drug that aims to reduce preterm births and that has become a flashpoint in the debate over the FDA’s accelerated approval pathway. Makena was granted accelerated approval in 2011, but subsequent clinical trials failed to demonstrate its effectiveness, leading FDA advisers last fall to recommend withdrawing the drug from the market. “While we stand by Makena’s favorable benefit-risk profile, including its efficacy in women at highest risk of preterm birth, we are seeking to voluntarily withdraw the product and work with the FDA to effectuate an orderly wind-down,” Covis Chief Innovation Officer Raghav Chari, Ph.D., said in a statement. The move comes ahead of an anticipated final decision on Makena’s status by FDA Commissioner Robert Califf and Chief Scientist Namandjé Bumpus.

© 2023 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

pharmacists
September 14

‘Delinking’ PBM Pay From Drug Prices Comes With High Cost, Economist Argues

READ MORE
capitol-dome
September 14

House Committees Proffer Modest PBM Reform Bill

READ MORE
blurry-judge
September 14

Legal Challenges to Drug Price Negotiations Could Have Broad Implications

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today